Platelet inhibition on brand and generic clopidogrel chronic therapy

26 August 2018 (15:06 - 15:24)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Ahmad Soliman

Saud Al-Babtain Cardiac Center (SBCC), Dammam (Saudi Arabia)

3 More presentations in this session

Presentation thumbnail

Perceived or calculated bleeding risk in patients undergoing percutaneous coronary intervention: inside the post-pci prospective registry

Doctor M. Ferlini (Pavia, IT)

Presentation thumbnail

Are perceived or calculated bleeding risk related to dapt choice in patients undergoing percutaneous coronary intervention?

Doctor M. Ferlini (Pavia, IT)

Presentation thumbnail

Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS)

Associate Professor V. Serebruany (Baltimore, US)

Abstract Slides Video

Access the full session

Session thumbnail

Safety issues with anti-platelets drugs

The Event

ESC Congress 2018

26 August 2018 15:06 CET

You may be interested in

Congress Presentation

Is there an inter-manufacturer difference in generic clopidogrel response?

26 August 2022

Congress Presentation

Residual platelet activity and systemic inflammation in patients with chronic coronary syndrome in the context of aspirin monotherapy.

29 June 2021

Congress Presentation

Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis

1 September 2020

Congress Presentation

Efficacy and safety of P2Y12 inhibitors plus aspirin versus aspirin alone in ischemic stroke or high-risk transient ischemic attack: a meta-analysis of randomized controlled trials

2 September 2024

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources